This Chinese medicine stock rose to the close, with a cumulative increase of more than 30% in the past 5 days

On November 22, Jinling Pharmaceutical closed with a price of 9.
22 yuan, a turnover of 359 million, a turnover rate of 7.
94%, a price-to-earnings (TTM) of 40.
55, and a total market value of 4.
706 billion
.
According to the Oriental Wealth Network Market Center's ranking of the flow of individual stock funds yesterday, Jinling Pharmaceutical ranked first with a net inflow of more than 50 million yuan, and the net inflow of the main force reached 52.
1289 million
.
In addition, the stock rose 30.
87% in the past 5 days and 40.
96%
in the past 10 days.
The analysis believes that the reason for the 22nd limit of the stock is traditional Chinese medicine + cough granules + medical devices + medical beauty
.
Jinling Pharmaceutical's main business is drug production, sales and medical elderly care services
.
According to the 2022 half-year report, the composition of Jinling Pharmaceutical's operating income is: drug production and sales accounted for 53.
4%, medical revenue accounted for 45.
14%, and other industries accounted for 1.
46%.

In the pharmaceutical business, the company produces proprietary Chinese medicines and chemicals, and sells self-produced drugs and agent drugs and medical devices
.
The company's main products are: Choronin injection (mainly used for thromboangiitis obliterans, arteriosclerotic occlusion, cerebral thrombosis and sequelae, multiple Takayasutan, acute arterial embolism of the extremities, diabetic gangrene, venous thrombosis and thrombophlebitis, etc.
), ferrous succinate tablets (Sulifei, mainly used for the prevention and treatment of iron deficiency anemia), lentinan injection (mainly used for adjuvant treatment of malignant tumors), etc
。 It is worth mentioning that the company is involved in the planting + production + circulation of traditional Chinese medicine, and has built five modern GAP planting bases for APIs in Yunnan, Zhejiang, Henan and other places to promote the standardized green planting project of APIs and achieve the GAP goal
of Chinese medicinal materials planting.
The company has four major pharmaceutical production bases of Nanjing Jinling Pharmaceutical Factory, Hefei Limin Pharmaceutical Factory, Fuzhou Meifeng Pharmaceutical Factory and Zhejiang Tianfeng Pharmaceutical Factory, and all of them have passed the national GMP certification
.
Relying on two major commercial companies---- Nanjing Huadong Pharmaceutical Co.
, Ltd.
and Nanjing Yitong Pharmaceutical Co.
, Ltd.
, the company has established a relatively sound market network
in the country.
Both commercial companies have passed the national GSP certification, have offices in major cities and regions across the country, and have 30 Jinling pharmacies
.
In terms of medical service business, it is mainly provided
by Suqian Hospital, Yizheng Hospital and Anqing Hospital under the company.
In the elderly care rehabilitation business, it is provided by Huzhou Development (including rehabilitation specialized hospitals)
to which the company belongs.
It is reported that the business scope of Anqing Petrochemical Hospital under the company includes medical cosmetology; Nanjing Gulou Hospital Group Suqian People's Hospital has departments including burns, plastic surgery and cosmetology
.
In addition, on the news, the company also replied to investors on the interactive platform that the company's cicada cough granules have completed clinical research and are to be reported for production
.
According to the third quarterly report of 2022, the company achieved main revenue of 2.
054 billion yuan, a year-on-year decrease of 2.
71%; the net profit attributable to the parent was 92.
9466 million yuan, down 4.
69% from the same period last year; Deducted non-net profit of 86.
9361 million yuan, down 12.
73%
from the same period last year.
However, in terms of the third quarter of 2022 alone, the company's main revenue in a single quarter was 702 million yuan, a year-on-year increase of 1.
87%; The net profit attributable to the parent in a single quarter was 33.
7352 million yuan, a year-on-year increase of 56.
47%.

For the first three quarters of the results, the company said that the overall operation situation is in line with the development characteristics of the industry, and the performance is mainly driven by: through brand advantages and product efficacy, constantly consolidate the market share of key products, and the sales volume of ferrous succinate tablets (Sulifei) and Meiluoning injection remain stable; The company's affiliated medical institutions grasp the prevention and control of the epidemic with one hand, treat and save people with the other, overcome various adverse effects, and take effective measures to maintain stable operation
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.